NCI Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?” March 20, 2026Vol.52 No.11By Claire Marie Porter
NCI A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants March 20, 2026Vol.52 No.11By Paul Goldberg
NCI Letai: “From this point forward, it really is much more like business as usual at the NCI.” March 20, 2026Vol.52 No.11By Jacquelyn Cobb
NCI The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades agoLowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” February 13, 2026Vol.52 No.06By Jacquelyn Cobb
NCI NCAB ad hoc group approves seven new, reissue concepts February 13, 2026Vol.52 No.06By Sara Willa Ernst
NCI Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural researchThe group replaced the NCI Board of Scientific Advisors February 06, 2026Vol.52 No.05By Claire Marie Porter
NCI In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook December 05, 2025Vol.51 No.44By Jacquelyn Cobb
NCINews Analysis Cancer centers adapt to life without site visits as NIH changes CCSG review October 31, 2025Vol.51 No.40By Paul Goldberg
NCI Anthony G. Letai to be named NCI directorThe Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say September 25, 2025Vol.51 No.35By Claire Marie Porter and Paul Goldberg
